Patofisiologi dan Manajemen Terapi (SSJ) dan Nekrolisis Epidermal Toksik (NET)

Penulis

  • Rina Diana Bagian/ SMF Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokteran Universitas Sebelas Maret, RSUD Dr. Moewardi Surakarta
  • Muhammad Eko Irawanto Bagian/ SMF Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokteran Universitas Sebelas Maret, RSUD Dr. Moewardi Surakarta

DOI:

https://doi.org/10.56951/medicinus.v33i2.53

Kata Kunci:

Nekrolisis epidermis (NE), Stevens-Johnson

Abstrak

Nekrolisis epidermis (NE) adalah sindrom reaksi mukokutan akut yang ditandai dengan nekrosis dan pengelupasan epidermis yang luas serta dapat menyebabkan kematian. Lesi awal berupa makula eritematosa, kemudian berkembang secara progresif menjadi lesi lepuh kendur dan selanjutnya terjadi pengelupasan epidermis. Berdasarkan luas permukaan tubuh yang terlibat, NE diklasifikasikan menjadi tiga kategori, yaitu sindrom Stevens-Johnson (SSJ) jika luas lesi <10%, overlap SSJ-nekrolisis epidermal toksik (SSJ-NET) jika luas lesi 10-30% dan nekrolisis epidermal toksik (NET) jika luas lesi >30%. Patofisiologi NE belum diketahui dengan jelas hingga saat ini. Sindrom Stevens-Johnson (SSJ) dan nekrolisis epidermal toksik (NET) merupakan kondisi yang dapat menyebabkan kematian, oleh karena itu memerlukan penanganan yang cepat dan tepat. Mengidentifikasi kemungkinan penyebab dan memberikan perawatan yang diperlukan di rumah sakit diharapkan mampu meminimalisasi kejadian fatal akibat kondisi ini. Penanganan utama pada SSJ-NET adalah dengan menghentikan penggunaan substansi yang dicurigai sebagai penyebab. Terapi lain yang dapat diberikan masih cukup kontroversial, seperti pemberian corticosteroid, IVIG, plasmapheeresis, dan cyclosporine.

Referensi

Roujeau JC, Allanore LV. Epidermal necrolysis. Dalam: Lowell A Goldsmith, Stephen I Katz, Barbara A Gilchiest, Amy S Paller, David J Leffel KW, editor. Fitzpatrick’s Dermatology in General Medicine. Edisi ke-1. New York: Mc Graw Hill; 2012. h. 439– 48.

Prins C, French LE. Erythem multiforme, Steven Johnson syndrome and toxic epidermal necrolysis. Dalam: Jean L Bolognia, Joseph Lorizzo RPR, editor. Dermatology. Edisi ke- 3. Spain: Elsevier; 2012. h. 323–33.

Thaha MA. Sindrom Stevens-Johnson dan Nekrolisis Epidermal Toksis di RSUP MH Palembang Periode 2006 - 2008. Media Med Indones. 2009;43(5):234–9.

Hastuti R, Ulya I, Irawanto ME. Hubungan antara SCORTEN dengan terjadinya mortalitas pada pasien SSJ/ NET di Instalasi Rawat Inap RSUD dr. Moewardi Surakarta. Subdivisi Dermatologi Alergi Imunologi Bagian Ilmu Kesehatan Kulit & Kelamin FK UNS / RSUD Dr. Moewardi. Unpublished. 2016

Darmawan H. Sindrom Stevens-Johnson Diduga Akibat Siprofloksasin. Cdk-217. 2014;41(6):432–5.

Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98(12):998–1003. DOI: https://doi.org/10.1136/archdischild-2013-303718

Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed a R, Foster CS. Stevens- Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94(4):419-436-438, 456. DOI: https://doi.org/10.1016/S1081-1206(10)61112-X

Kariosentono H. Sindroma Steven Johnson. Dalam: Mochtar M, editor. Penyakit Kulit Gawat Darurat. Edisi ke 1. Surakarta: UPT. Penerbitan dan Pencetakan UNS; 2015. h. 1– 15.

Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis - part of the Stevens-Johnson syndrome spectrum. J der Dtsch Dermatologischen Gesellschaft. 2012;10(10):740–5. DOI: https://doi.org/10.1111/j.1610-0387.2012.07951.x

Breathnach S. Erytem multiforme, Steven Johnson syndrome and toxic epidermal necrolysis. Dalam: Tony Burns, Stephen Breathnach, Neil Cox CG, editor. Rook’s Textbook of dermatology. Edisi ke-8. Atrium: Blackwell Publishing; 2010. h. 76.1-9. DOI: https://doi.org/10.1002/9781444317633.ch76

Chung WH, Lee HY. Toxic epidermal necrolysis: the year in review. Rev Anaesthesiol Intensive Ther. 2013;13(4):330–6 DOI: https://doi.org/10.1097/ACI.0b013e3283630cc2

Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, dkk. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155–61. DOI: https://doi.org/10.1067/mai.2002.120563

Su SC, Chung WH. Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatologica Sin. 2103;31(4):175–80. DOI: https://doi.org/10.1016/j.dsi.2013.09.002

Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol. 2002;2(6):401–9. DOI: https://doi.org/10.1038/nri819

Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schöpf E. Low N- acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol. 1995;4(5):313–6. DOI: https://doi.org/10.1111/j.1600-0625.1995.tb00211.x

Nickoloff BJ. Saving the skin from drug-induced detachment. Nat Med. 2008;14(12):1311–3. DOI: https://doi.org/10.1038/nm1208-1311

Dao RL, Su SC, Chung WH. Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. Asia Pac Allergy. 2015;5:59–67. DOI: https://doi.org/10.5415/apallergy.2015.5.2.59

Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285–306. DOI: https://doi.org/10.2217/pgs.12.108

Roujeau JC. Immune mechanisms in drug allergy. Allergol Int. 2006;55(1):27–33. DOI: https://doi.org/10.2332/allergolint.55.27

Chung WH, Chang WC, Lee YS, Wu YY, Yang -H, Ho HC, dkk. Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions. JAMA. 2014;312(5):525. DOI: https://doi.org/10.1001/jama.2014.7859

Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, dkk. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–64.22. Jennifer T Trent, Ma Frangchao, Kerdel F, Fien S, French LE, Romanelli P, dkk. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol. 2007;2(3):299–303. DOI: https://doi.org/10.1586/17469872.2.3.299

Jolanta Maciejewska, Marek Jankowski, Barbara Zegarska. Stevens-Johnson syndrome/ toxic epidermal necrolysis presumably induced by norfloxacin. Dermatol Alergol. 2014;31(3):194–196. DOI: https://doi.org/10.5114/pdia.2014.40796

Kazuhisa Hirahar, Yoko Kano. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/ toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013; 69(3):496–498. DOI: https://doi.org/10.1016/j.jaad.2013.04.007

Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, dkk. Toxic epidermal necrolysis: Analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005;85(6):497–502.

Michaels B, Rosso JQ Del. The Role of Systemic Corticosteroid Therapy in Erythema Multiforme Major and Stevens-Johnson Syndrome A Review of Past and Current Opinions. J Clin Aesthet Dermatol. 2009;2(3):51–5.

Endorf FW, Cancio LC, Gibran NS. Toxic Epidermal Necrolysis Clinical Guidelines. J Burn Care Res. 2008; 29(5):706–12. DOI: https://doi.org/10.1097/BCR.0b013e3181848bb1

Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, dkk. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50. DOI: https://doi.org/10.1038/nm.1884

Hung PC, Wang HS, Hsia SH, Wong AMC. Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy. Brain Dev. 2014;36(4):356–8. DOI: https://doi.org/10.1016/j.braindev.2013.05.010

St. John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, dkk. Successful Use of Cyclosporin A for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children. Pediatr Dermatol. 2017;34(5):540–6. DOI: https://doi.org/10.1111/pde.13236

Swosti Mohanty, Anupam Das, Anupama Ghosh AS, Ramesh Chandra Gharami, Debabrata Bandyopadhyay NK Das. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study. Indian J Dermatol Venereol Leprol. 2017;83(3):312–6. DOI: https://doi.org/10.4103/ijdvl.IJDVL_201_16

Diterbitkan

01-08-2020

Unduhan

Data unduhan tidak tersedia.

Cara Mengutip

[1]
Patofisiologi dan Manajemen Terapi (SSJ) dan Nekrolisis Epidermal Toksik (NET). MEDICINUS 2020;33:50-62. https://doi.org/10.56951/medicinus.v33i2.53.